

**4th Global Conference on Myositis (GCOM)
June 6 – June 9, 2022, Prague, Czech Republic**

PRELIMINARY PROGRAM

<i>Monday, June 6, 2022</i>		
8:00		Arrivals, registration
10:30 - 12:45		Pre-congress Workshop – Pathology
-		Chairs: Anthony Amato (USA), Werner Stenzel (Germany), Ichizo Nishino (Japan)
12:45 -		Lunch
13:45 - 13:50	0:05	Welcome: Jiri Vencovsky (Czech Republic)
13:50 - 15:20		General Session I. Pathogenesis, including mitochondrial biology
		Chairs: Tahseen Mozaffar, Merrilee Needham
	0:25	Molecular pathology of mitochondrial disorders (Peter Rehling , Germany)
	0:25	Role of mitochondria in skeletal muscle dysfunction in myositis (Kanneboyina Nagaraju , USA)
	0:12	Discovery of antigen specific CD4+ T cells in anti-HMGCR-positive immune mediated necrotizing myopathy (Eleni Tiniakou , USA)
	0:12	An approach combining transcriptomic and topographic analysis reveals a potential role of proteasome and autophagy deregulation in the pathophysiology of dermatomyositis (Debrut Léa , France)
	0:12	Effect of type I interferon on engineered human skeletal muscle: A promising model for juvenile dermatomyositis (Lauren Covert , USA)
15:20 - 15:30		Break
15:30 - 16:45		General Session II. Genes and environment
		Chairs: Fred Miller, Janine Lamb
	0:25	Defining causal genes at MHC in SLE – implications for myositis and other diseases that share MHC risk (Tim Vyse , UK) online
	0:25	Novel machine learning tools identify novel host-specific and environmental factors in myositis (Christopher Amos , USA)
	0:12	Familial associations of autoimmune diseases in patients with idiopathic inflammatory myopathies - A Swedish population-based study (Weng Ian Che , Sweden)
	0:12	Low gene copy numbers of complement C4 and complement C4A deficiency are strong and highly significant genetic risk factors for idiopathic inflammatory myopathy and its major subgroups (Chack-Yung Yu , USA)
16:45 - 17:15	0:30	Coffee Break
17:15 - 18:45		General Session III. Inclusion body myositis
		Chairs: Mazen Dimachkie, Tom Lloyd
	0:25	Selective T Cell Depletion for Inclusion Body Myositis: Why and How (Steve Greenberg , USA)
	0:25	IBM in 2022: from physiopathogenesis to clinical trials (Olivier Benveniste , France)

-	0:12	A randomized, double-blind, placebo-controlled study of arimoclomol in patients with inclusion body myositis (Mazen Dimachkie, USA)
-	0:12	Atypical presentations of inclusion body myositis: clinical characteristics and long-term outcomes (Elie Naddaf, USA)
	0:12	Do virus-specific memory T cells contribute to inclusion body myositis? (Jerome Coudert, Australia)
19:00		Networking

Tuesday, June 7, 2022		
8:30 - 10:10		General Session IV. Antibodies and biomarkers
		Chairs: Albert Selva-O'Callaghan, Valerie Leclair
	0:12	Identification of cell types and gene expression programs associated with juvenile dermatomyositis using multiplexed single-cell RNA sequencing and matrix factorization (Jessica Neely, USA) online
	0:25	Reliability of immunoassays for myositis autoantibodies (Sarah Tansley, UK) online
	0:25	Autoantibodies and complement in experimental IMNM: from pathogenesis to therapy? (Olivier Boyer, France)
	0:25	Novel biomarkers predict whether cancer emerges in anti-TIF1 γ -positive DM patients at high risk for cancer (Livia Casciola-Rosen, USA)
	0:12	Anti-FHL1 autoantibodies in adult myositis patients: baseline and longitudinal follow-up analysis (Angeles Shunashy Galindo-Feria, Sweden)
10:10 - 10:55		Coffee Break - POSTER Session I
10:55 - 12:40		General Session V. Juvenile myositis/Juvenile to adult transition
		Chairs: Lisa Rider, Lucy Wedderburn
	0:25	When JM patients lose their 'J': transition challenges in myositis care (Rebecca Sadun, USA)
	0:25	Physical fitness in long-term JDM (Kristin Schjander Bernsten, Norway)
	0:25	Fatigue and well-being of children with chronic inflammatory disease (Sanne Nijhof, Netherlands)
-	0:12	Mental health screening in juvenile myositis: interim analysis of a pilot study (Kaveh Ardalan, USA)
-	0:12	Adipose tissue distribution is associated with cardiac dysfunction in adult patients with juvenile-onset dermatomyositis (Henriette Schermacher Marstein, Norway)
12:40	1:00	Lunch
13:40 - 14:50		General Session VI. COVID-19 and myositis
		Chairs: Julie Paik, Yves Allenbach
	0:25	EULAR COVID and COVAX registries' update: focus on myositis (Pedro Machado, UK)
	0:12	COVID-19 outcomes in patients with dermatomyositis: a registry-based cohort analysis (Parikshit Sen, India)
	0:12	SARS-CoV-2 associated myopathy (Tom Aschman, Germany)
	0:12	Humoral response to 3rd dose SARS-CoV-2 vaccine in patients with idiopathic inflammatory myopathies (Caoilfhionn Connolly, USA)

14:50 - 15:35		Coffee Break - POSTER Session II
15:35 - 16:50		General Session VII. Imaging in myositis
		Chairs: Marianne de Visser, Pierre Carlier
	0:25	MRI in myositis (Pierre Carlier, France)
	0:25	Muscle ultrasound for myositis (Jemima Albayda, USA)
-	0:12	Muscle B mode ultrasound and shear-wave elastography in idiopathic inflammatory myopathies: Validation against MRI and muscle biopsy findings in an incident patient cohort (SWIM study). (Shereen Paramalingam, Australia)
-	0:12	Use of 18-FDG PET-CT in idiopathic inflammatory myopathies, a retrospective series of 93 examinations. A tool with uncertain performances. (Samy Mensi, France)
15:50 - 16:50		Scientific interest groups (SIG)
		SIG: Rehabilitation & Exercise (Helene Alexanderson)
16:50 - 17:00		Break
17:00 - 19:00	2:00	Workshop I: Juvenile dermatomyositis (supported by Cure JM Foundation)
		Chairs: Annet van Royen, Pavla Doležalová
	0:20	Oxidised mitochondrial DNA: a new therapeutic target in Juvenile Dermatomyositis. (Meredyth Wilkinson, UK)
	0:20	A plasma-induced transcriptome signature in treatment-resistant juvenile and adult myositis patients is associated with activated IFN, IL-6 and inhibited IL-15 signalling pathways, as well as regulators of NK and CD4 T cell differentiation. (Sara Sabbagh, USA)
	0:20	Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis. (Melissa Morales, USA)
	0:20	Plasma proteomic signatures in juvenile dermatomyositis define novel differentially regulated proteins in treatment naïve patients and are distinct from childhood-onset lupus. (Jessica Turner, USA)
	0:20	Siglec-1 reflects the dysregulated type I IFN pathway and can predict treatment response in JDM. (Saskia R. Veldkamp, Netherlands)
	0:20	Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index (Silvia Rosina, Italy)
17:00 - 19:30	2:30	Workshop II: Physiotherapy and Occupational Therapy.
		Chairs: Hana Šmucrová, Helene Alexanderson
	0:15	Exercise is medicine - positive effects on physical capacity, quality of life and disease activity in myositis (Helene Alexanderson, Sweden)
	0:15	Training focused on activities of daily living (ADL) in idiopathic inflammatory myopathies (Maja Špiritović, Czech Republic)
	0:30	Occupational therapy for people with idiopathic inflammatory myopathies (Hana Šmucrová, Czech Republic, Malin Regardt, Sweden)
	0:30	Practical demonstration of ADL - exercise and hand exercise for myositis, patient perspective of exercise (Maja Špiritović, Hana Šmucrová, Malin Regardt, Olga Drápalová, Czech Republic)
	1:00	Q&A
18:30 - 19:30		Scientific interest groups (SIG)
		SIG: Outcome assessment (Pedro Machado and Vickie Werth)
		SIG: Inclusion body myositis (Tom Lloyd and Bhaskar Roy)

Wednesday, June 8, 2022		
8:30 - 9:15		Keynote lecture
		Chair: Ingrid Lundberg, Rohit Aggarwal
	0:45	Interstitial lung disease in myositis (Sonye Danoff, USA)
9:15 - 10:45		General Session VIII. Skin in myositis
		Chairs: Victoria Werth, Iago Pinal-Fernandez
	0:25	The neuroimmune basis of chronic itch (Brian Kim, USA) online
	0:25	Outcomes, biomarkers, and novel treatments for the skin in dermatomyositis (Victoria Werth, USA)
	0:12	Lesional and non-lesional dermatomyositis keratinocytes share IFN signature with lupus but display distinct pathway phenotypes (Grace A. Hile, USA)
	0:12	Photosensitivity in the skin of patients with dermatomyositis is associated with type I interferon induction of CXCL13-producing T peripheral helper cells. (Khashayar Afshari, USA)
	0:12	Non-invasive tape stripping in juvenile dermatomyositis highlights interferon signature in lesional skin and upregulation of metabolic signalling pathways in non-lesional skin (Jessica L. Turnier, USA)
10:45 - 11:30		Coffee Break - POSTER Session III
11:30 - 12:45		General Session IX. Drug-induced myositis
		Chairs: Jens Schmidt, Louise Diederichsen
	0:25	Myositis triggered by checkpoint inhibitors (Yves Allenbach, France)
	0:25	Myositis triggered by statins (Andrew Mammen, USA)
-	0:12	The transcriptomic profile of muscle biopsies from patients with immune checkpoint inhibitor-induced myopathy (Andrew L Mammen, USA)
-	0:12	Immune checkpoint inhibitor-related myotoxicity: musculoskeletal and/or neuromuscular junction disorder? (Lotta Plomp, France)
-		
12:45 -		Lunch
		Symposia
13:40 - 14:25		Octapharma Symposium: IVIG in dermatomyositis: Exploring the evidence for efficacy and safety
		Chairs: Jiří Vencovský, Rohit Aggarwal
	0:05	Welcome and Introduction
	0:15	Unmet needs and IVIG as emerging therapy (Rohit Aggarwal, USA)
	0:10	Personal experience with anti-NXP-2 positive patients in the ProDERM study (Jiri Vencovsky, Czech Republic)
	0:10	The importance of measuring skin disease in dermatomyositis (Victoria Werth, USA)
	0:05	Discussion All
14:30 - 15:00		Lysosomal storage diseases at the rheumatologist (Industry symposium sponsored by Takeda)
		Chair: Jiri Vencovsky

		Some Fabry disease symptoms can lead the patient to a rheumatologist (Aleš Linhart , Czech Republic)
		Manifestations of skeletal and joint impairment in morbus Gaucher and Hunter syndrome patients (Stella Mazurová , Czech Republic)
15:00 - 15:45		Coffee Break - POSTER Session IV
15:45 - 16:30		International Myositis and Clinical Study Groups (IMACS) meeting (Lisa Rider, David Isenberg, Hector Chinoy, Mazen Dimachkie)
16:30 - 16:35		Report from the PReS JDM working group (Liza McCann)
16:35 - 17:35		International Myositis Society meeting (Jens Schmidt)
17:35 - 18:35		Scientific interest groups (SIG)
		SIG: Myositis genetics (Janine Lamb and Chris Amos)
		SIG: Telemedicine (Lisa Christopher-Stine)
		SIG: Committee on international code of diseases (Iazsmin Bauer-Ventura)
19:00		Scientific Get-together

Thursday, June 9, 2022		
8:30 - 10:00		General Session X. Toward personalised treatment
		Chairs: Hector Chinoy, Lisa Christopher-Stine
	0:25	Personalized and precision medicine in multiple sclerosis: subgroup discovery and care improvements in Johns Hopkins inHealth (Ellen Mowry, USA)
	0:25	Precision medicine of Rheumatoid Arthritis (John Isaacs, UK)
-	0:12	Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of subcutaneous abatacept in adults with active idiopathic inflammatory myopathy. (Rohit Aggarwal, USA)
-	0:12	Muscle T cell signatures and clonally expanded cytotoxic T cells are identified in idiopathic inflammatory myopathies using single cell sequencing. (Alexandra Argyriou, Sweden)
-	0:12	The ProDERM study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of IVIg (Octagam 10%) in patients with active dermatomyositis. (Rohit Aggarwal, USA)
10:00 - 10:45		Deep insights into the interstitial lung diseases (Satellite symposium sponsored by Boehringer-Ingellheim)
		Chair: Martina Koziar Vašáková
	0:20	Pathophysiology of interstitial lung diseases (Martina Koziar Vašáková, Czech Republic)
	0:20	HRCT imaging of interstitial lung diseases (Eva Kočová, Czech Republic)
	0:05	Discussion
10:45 - 11:15		Coffee Break
11:15 - 12:05		General Session XI. Repairing damage
		Chairs: Helene Alexanderson, Anneke van der Kooi
12:00 - 12:25	0:25	Repairing damage: Focus on muscle and physical function (Susan Maillard, UK)
-	0:12	Performance of Sit-to-Stand, Timed Up-and-Go and Six-Minute Walk Tests in the Home and Office Setting (Didem Saygin, USA)
-	0:12	Sarcopenia in myositis patients: a marker of muscle damage associated with myositis severity and disability (Margherita Giannini, France)

12:25 - 13:15		Patients: reports from patient associations
-		Reports from patients' organisations
		Chairs: Lisa Christopher-Stine
13:15 - 13:45		General Discussion, Prizes, Closing + Handover
		Jiri Vencovsky, Jens Schmidt
13:45		Lunch